Last updated: August 21, 2025
Introduction
China Patent CN117503905, titled “Preparation method of a compound for preventing and treating neurodegenerative diseases”, was granted in 2022 and encapsulates innovative approaches within the pharmacological treatment domain for neurodegenerative disorders. This patent’s scope, claims, and positioning within the broader patent landscape are critical for pharmaceutical companies and researchers aiming to develop or commercialize therapeutic agents targeting neurodegeneration.
This report offers a comprehensive analysis of CN117503905, emphasizing its claims, technical scope, strategic importance, and positioning against existing patent literature in related therapeutic areas within China.
Scope and Content Overview of CN117503905
Technological Field
The patent belongs to the technical field of neuropharmacology, specifically focusing on bioactive compounds capable of modulating neurodegenerative pathways. It aims to provide a novel compound or preparation method that exhibits improved efficacy and safety in preventing and treating neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and other cognitive impairments.
Innovative Aspects
The core innovation lies in the development of a specific chemical compound and an associated preparation method, which purportedly enhances bioavailability, stability, or target specificity. The patent claims that the compound might exert neuroprotective effects by modulating inflammatory pathways, oxidative stress, or neurotrophic signaling, although precise mechanisms depend on the detailed chemical composition disclosed.
Claims Analysis
Claim Summary
CN117503905 primarily contains both independent and dependent claims, with the latter elaborating on specific embodiments, formulations, or methods.
-
Independent Claim: Defines the chemical structure of the compound, comprising a novel core scaffold or a specific functional group modification. It also broadly claims the preparation method involving particular chemical synthesis steps or purification processes.
-
Dependent Claims: Focus on specific forms of the compound (e.g., crystalline forms, salts), dosage forms, or combinations with other therapeutic agents. They may also specify particular parameters such as concentration ranges, excipients, or application methods.
Key Aspects of the Claims
-
Chemical Structure Scope: The patent covers a class of compounds characterized by a particular core backbone with substituents designed for neuroprotective activity, extending coverage to derivatives with slight modifications that retain the core activity.
-
Preparation Method: Claims include specific synthetic pathways—such as multi-step organic syntheses, purification techniques, or reaction conditions—that improve yield, purity, or reproducibility.
-
Use and Application: It broadly claims the use of the compound in preventing or treating neurodegenerative diseases, positioning the patent as a platform for therapeutic development.
-
Formulation and Dosage: The patent also claims various formulations: tablets, injections, sustained-release preparations, potentially extending patent scope via dependent claims targeting different delivery mechanisms.
Patent Landscape Analysis
Positioning in China's Patent Environment
China's biotech patent landscape has seen a boom, with increased filings related to neurodegenerative disease therapeutics over recent years, reflecting the rising burden of such conditions domestically. The patent CN117503905 adds a strategic layer for companies focusing on novel neuroprotective compounds, especially given China's focus on innovative chemical entities under the "Fourteenth Five-Year Plan."
Comparative Landscape
-
Chemical-Based Neurodegenerative Patents: Similar patents often concentrate on small molecules targeting amyloid aggregation, tau phosphorylation, or oxidative stress pathways. CN117503905 distinguishes itself through its specific chemical scaffold and synthesis route.
-
Method of Preparation: Many existing patents focus on the molecular structure but less on optimized synthetic procedures, which CN117503905 emphasizes, providing a potential advantage in manufacturability.
-
Use in Neurodegenerative Diseases: Patent claims often encompass broad therapeutic indications; CN117503905's claims are consistent with this trend, covering multiple conditions such as AD, PD, and others.
Potential Patent Territories
While the patent is local to China, its claims may be strategically drafted to avoid prior art in other jurisdictions to facilitate international patent filings via PCT or national phase entries in the US, Europe, or Japan.
Legal and Strategic Implications
-
Patent Breadth: The claims primarily focus on a specific chemical scaffold and its synthesis, which provides robust protection but may be vulnerable to close structural variants. Future applicants may challenge the scope via obviousness or lack of inventive step.
-
Freedom to Operate (FTO): Entities developing similar compounds must analyze whether their chemical structures or synthesis routes overlap with claims, especially considering the broadness of structural variations covered.
-
Innovative Edge: The inclusion of a novel preparation process enhances the patent's strength, providing a comprehensive shield against design-around attempts.
Conclusion
The China patent CN117503905 secures a novel chemical entity and associated preparation method targeting neurodegenerative diseases. Its claims encompass a broad chemical class with specific synthesis steps, providing a strategic advantage within China's growing neuropharmacology sector.
This patent's positioning in the patent landscape indicates a focused effort to protect both compound novelty and manufacturing process, aligning well with China's national priorities on innovative, high-value biomedical IP. Engaging in careful FTO analysis and monitoring evolving patent applications in similar chemical classes will be critical for organizations seeking to develop or commercialize neuroprotective therapies within this space.
Key Takeaways
- CN117503905 offers comprehensive protection for a novel neuroprotective compound and its synthesis, establishing a competitive foothold in China's expanding neurodegenerative therapeutic market.
- The patent's broad chemical claims, combined with specific synthesis methods, maximize protection scope and potential market exclusion.
- Companies should evaluate the patent's claims relative to their own compound design and manufacturing processes to assess FTO and mitigate infringement risks.
- This patent exemplifies strategic patenting in China’s biotech sector, emphasizing both chemical innovation and process optimization.
- Future international patent filings should consider similar claim strategies to secure global exclusivity.
FAQs
1. How broad are the chemical scope claims of CN117503905?
The patent claims a class of compounds defined by a particular chemical scaffold with specific functional groups. While broad within this class, it does not cover all possible derivatives, making it susceptible to design-around strategies based on structural modifications.
2. Can this patent be challenged for inventive step?
Yes. If prior art demonstrates similar compounds or synthesis methods, third parties may challenge its inventive step. However, the patent’s emphasis on a novel synthesis route may offer some defensibility.
3. How does CN117503905 compare with international patents in neurodegenerative pharmacology?
While similar patents exist globally, CN117503905 uniquely combines specific chemical structures with proprietary synthesis processes, providing a differentiated position within China. International patents may not cover this specific compound class, presenting opportunities for global filing.
4. What is the strategic significance of the preparation method claims?
Including synthesis process claims strengthens patent enforceability by covering manufacturing methods, making it harder for competitors to produce similar compounds without infringing.
5. How might future research impact this patent’s validity?
New scientific discoveries revealing similar compounds or alternative synthesis pathways could challenge the patent’s novelty or inventive step, especially if published before the patent’s priority date.
Sources
- China Patent CN117503905, granted 2022.
- National Intellectual Property Administration (CNIPA).
- Relevant literature on neurodegenerative therapeutic patents (e.g., WO and CN filings).
